12.35
前日終値:
$12.39
開ける:
$12.39
24時間の取引高:
215.40K
Relative Volume:
0.53
時価総額:
$510.29M
収益:
$313.73M
当期純損益:
$-31.39M
株価収益率:
-16.26
EPS:
-0.7597
ネットキャッシュフロー:
$-3.53M
1週間 パフォーマンス:
+1.65%
1か月 パフォーマンス:
+3.61%
6か月 パフォーマンス:
-6.16%
1年 パフォーマンス:
+23.62%
Angiodynamic Inc Stock (ANGO) Company Profile
Compare ANGO vs ISRG, BDX, ALC, MDLN, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ANGO
Angiodynamic Inc
|
12.35 | 502.02M | 313.73M | -31.39M | -3.53M | -0.7597 |
|
ISRG
Intuitive Surgical Inc
|
403.18 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
143.92 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
66.12 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
35.30 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
191.26 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-16 | 開始されました | Lake Street | Buy |
| 2024-04-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-09-25 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-17 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-10-15 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-08-20 | 開始されました | Oppenheimer | Perform |
| 2020-11-25 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2020-04-08 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-01 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2018-04-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-01-05 | ダウングレード | Craig Hallum | Buy → Hold |
| 2017-04-07 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-03-30 | ダウングレード | KeyBanc Capital Mkts | Overweight → Sector Weight |
| 2017-02-08 | 開始されました | Barclays | Equal Weight |
| 2016-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-04-08 | 再開されました | Piper Jaffray | Neutral |
| 2016-01-08 | 繰り返されました | Canaccord Genuity | Buy |
| 2015-11-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2015-07-24 | 開始されました | KeyBanc Capital Mkts | Overweight |
| 2014-06-19 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2012-10-09 | 繰り返されました | Canaccord Genuity | Hold |
| 2012-06-25 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2011-07-15 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2011-07-15 | アップグレード | Stifel Nicolaus | Hold → Buy |
| 2011-06-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2010-09-08 | 繰り返されました | Wedbush | Neutral |
すべてを表示
Angiodynamic Inc (ANGO) 最新ニュース
AngioDynamics Inc (ANGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AngioDynamics Inc (ANGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AngioDynamics Inc (ANGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AngioDynamics Inc (ANGO) Institutional Confidence - TradingKey
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow - Seeking Alpha
ANGO News | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Webcast set for AngioDynamics talk at Goldman Sachs health event - Stock Titan
Reasons to Add AngioDynamics Stock to Your Portfolio for Now - Yahoo Finance
Point72 (ANGO) reports 3.18M shares, 7.7% stake via Point72 Associates - Stock Titan
Prostate cancer trial sees 0 new failures with NanoKnife at 2 years - Stock Titan
AngioDynamics alleges patent infringement by E2 over clot removal technology - MassDevice
[8-K] ANGIODYNAMICS INC Reports Material Event - Stock Titan
Fair Value Assessment | AngioDynamics Inc. posts 117.8% EPS surprise beating loss estimatesEarnings Risk - Cổng thông tin điện tử tỉnh Tây Ninh
AngioDynamics files patent lawsuit against Endovascular Engineering - Investing.com
ANGO (AngioDynamics Inc.) notches massive Q1 2026 EPS beat, but shares fall 1.24 percent on slight year over year revenue decline.Social Trade Signals - Xã Thanh Hà
AngioDynamics (ANGO) Upgraded to Buy: Here's Why - Yahoo Finance
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down - TradingView
AngioDynamics Growing, But With More Noise Than The Street Likes (NASDAQ:ANGO) - Seeking Alpha
AngioDynamics Inc. Q3 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements Overview - Minichart
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2026 Earnings Call Transcript - Insider Monkey
AngioDynamics (NASDAQ: ANGO) Q3 2026 revenue up 9% while net loss grows - Stock Titan
AngioDynamics, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
AngioDynamics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:ANGO) 2026-04-02 - Seeking Alpha
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance - ChartMill
AngioDynamics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
AngioDynamics investors can watch Needham conference webcast April 14 - Stock Titan
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0% - Defense World
AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
AngioDynamics, Inc. (ANGO) Investor Outlook: Unpacking A 71.55% Potential Upside - DirectorsTalk Interviews
Vanguard disaggregates holdings; reports 0 shares in AngioDynamics (ANGO) - Stock Titan
AngioDynamics, Inc. (ANGO) Stock Analysis: A Potential 81.88% Upside For Investors - DirectorsTalk Interviews
AngioDynamics schedules April 2 earnings call before market open - Stock Titan
Bard And AngioDynamics Resolve 11-Year Patent Dispute - Law360
AngioDynamics, Inc. $ANGO Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update - MarketBeat
AngioDynamics, Inc. (ANGO) Investor Outlook: An 80% Upside Potential Amid Strategic Healthcare Innovations - DirectorsTalk Interviews
AngioDynamics CEO Details Portfolio Shift as Auryon, AlphaVac and NanoKnife Fuel Growth at Conference - Yahoo Finance
Veeva Systems' Stock Up After Q4 Earnings & Revenues Beat Estimates - Finviz
AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 17.6% - MarketBeat
AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 68.70% Potential Upside Amid Healthcare Innovations - DirectorsTalk Interviews
TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates - Finviz
Hear AngioDynamics CEO Jim Clemmer live at Leerink healthcare conference - Stock Titan
Can AngioDynamics Inc. stock maintain growth trajectoryWeekly Trade Review & Fast Gain Stock Trading Tips - mfd.ru
AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 72.62% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Is AngioDynamics Inc. a top pick in the sectorAnalyst Upgrade & Verified Technical Signals - mfd.ru
Bastion Asset Management Inc. Buys 304,960 Shares of AngioDynamics, Inc. $ANGO - MarketBeat
Will AngioDynamics Inc. benefit from rate cutsEarnings Risk Summary & Technical Confirmation Trade Alerts - mfd.ru
Angiodynamic Inc (ANGO) 財務データ
収益
当期純利益
現金流量
EPS
Angiodynamic Inc (ANGO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Trowbridge Stephen A | EVP and CFO |
Oct 13 '25 |
Buy |
11.16 |
890 |
9,932 |
256,629 |
| Clemmer James C | President and CEO |
Oct 09 '25 |
Buy |
11.15 |
10,000 |
111,500 |
882,529 |
大文字化:
|
ボリューム (24 時間):